Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A protein-like 1 (TCEAL1) is a nuclear phosphoprotein belonging to the transcription elongation factor A (SII)-like (TCEAL) gene family, encoded on the human X chromosome at Xq22.2[1][3]. It modulates transcription in a promoter context-dependent manner, likely through protein-protein interactions with other transcriptional regulators rather than direct DNA binding[1][3]. The protein contains a zinc finger-like motif and a sequence related to the Pol II-binding region of transcription factor SII[1][3]. Variants in TCEAL1 have recently been implicated in neurodevelopmental disorders characterized by developmental delay, intellectual disability, autism spectrum disorder-like behaviors, hypotonia, gait abnormalities, and mild craniofacial dysmorphism[2][7]. The full disease spectrum is still being defined, but TCEAL1 appears to be essential for proper transcriptional regulation in neurons and other cell types[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A protein-like 1 (TCEAL1).